Icotinib

Drug Profile

Icotinib

Alternative Names: BPI-2009; BPI-2009H; Commana; Conmana; Icotinib hydrochloride

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Zhejiang Beta Pharma
  • Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Brain metastases; Nasopharyngeal cancer; Oesophageal cancer
  • Phase I Pancreatic cancer; Psoriasis

Most Recent Events

  • 07 Oct 2016 Safety and efficacy data from the phase III CONVINCE trial presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Jul 2016 Phase-I clinical trials in Psoriasis in China (Topical) (NCT02801435)
  • 14 Jun 2016 Betta Pharmaceuticals plans a phase I trial for Psoriasis in China (Topical, Cream) (NCT02801435)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top